USPTO Issues Patent To Cleveland CBLB502

The US Patent and Trademark Office (USPTO) has issued US Patent No 7638485 titled ‘Modulating Apoptosis’ covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. The patent was already granted by the nine member countries of the Eurasian Patent Organisation (EAPO), and two additional nations.

Cleveland has also filed two additional new patent applications related to Protectan technology in the US around various aspects and properties for CBLB502 and related Protectan compounds, including new methods of use of flagellin derivatives and screening for new compounds with similar properties.

Yakov Kogan, chief operating officer of Cleveland, said: “With more than 13 sets of patents filed to date in the US and internationally around various properties of CBLB502 and related compounds, we believe we have protected the potentially broad uses of our Protectan technology.

“The receipt of our first US patent for protection from radiation is a major milestone in our development of CBLB502 and we continue to advance our work in this and other areas of protection from acute stresses.”